Forest's ceftaroline meets cSSSI endpoint

Forest (NYSE:FRX) said ceftaroline met the primary endpoint of a clinical cure rate that was non-inferior to vancomycin plus aztreonam in the Phase III CANVAS I and CANVAS II trials to treat complicated skin and skin structure infections (91.6% vs. 92.7%). Ceftaroline, a cephalosporin antibiotic, had a microbiological eradication rate of 92.4% vs. 93.6% for vancomycin plus aztreonam. In microbiologically evaluable patients, ceftaroline had a clinical cure rate of 93.1% for Staphylococcus aureus infections and 93.3% for methicillin-resistant S. aureus (MRSA) infections. The double-blind, international studies enrolled 1,396 patients. Detailed results will be presented at a conference this year. ...